Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 6, 2006, Pages 626-632

  Aronson, Doron ^a   Roterman, Inon ^b   Yigla, Mordechay ^b   Kerner, Arthur ^b   Avizohar, Ophir ^b   Sella, Ron ^b   Bartha, Peter ^b   Levy, Yishai ^b   Markiewicz, Walter ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b NONE

Author keywords

C reactive protein; Forced vital capacity; Obesity; Physical fitness; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FITNESS; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; INFLAMMATION; LUNG DISEASE; LUNG FUNCTION; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPIRATORY SYSTEM; RESTRICTIVE LUNG DISEASE; SEX; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; EXERCISE; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; SMOKING; VITAL CAPACITY;

EID: 33748697828     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200602-243OC     Document Type: Article

References (38)

1. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-715.
2. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-1959.
3. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-664.
4. Schroeder EB, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003;158:1171-1181.
5. Tockman MS, Pearson JD, Fleg JL, Metter EJ, Kao SY, Rampal KG, Cruise LJ, Fozard JL. Rapid decline in FEV1: a new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995;151:390-398.
6. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-762.
7. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
8. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765.
9. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in COPD. Am J Respir Crit Care Med 2006;174:6-14.
10. Engstrom G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgarde F. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106:2555-2560.
11. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18:60-65.
12. Maestrelli P, Saetta M, Mapp CE, Fabbri LM. Remodeling in response to infection and injury: airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:S76-S80.
13. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
14. Collins LC, Hoberty PD, Walker JF, Fletcher EC, Peiris AN. The effect of body fat distribution on pulmonary function tests. Chest 1995;107:1298-1302.
15. Lazarus R, Sparrow D, Weiss ST. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest 1997;111:891-898.
16. Jakes RW, Day NE, Patel B, Khaw KT, Oakes S, Luben R, Welch A, Bingham S, Wareham NJ. Physical inactivity is associated with lower forced expiratory volume in 1 second: European Prospective Investigation into Cancer-Norfolk Prospective Population Study. Am J Epidemiol 2002;156:139-147.
17. World Health Organization Expert Committee. Physical status: the use and interpretation of anthropometry. WHO Tech Rep Ser No 854. Geneva: World Health Organization; 1995.
18. Aronson D, Sella R, Sheikh-Ahmad M, Kerner A, Avizohar O, Rispler S, Bartha P, Markiewicz W, Levy Y, Brook GJ. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol 2004;44:2003-2007.
19. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 1973;85:546-562.
20. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
21. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-187.
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
23. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996;9:1989-1994.
24. Riediker M, Cascio WE, Griggs TR, Herbst MC, Bromberg PA, Neas L, Williams RW, Devlin RB. Particulate matter exposure in cars is associated with cardiovascular effects in healthy young men. Am J Respir Crit Care Med 2004;169:934-940.
25. Mukae H, Vincent R, Quinlan K, English D, Hards J, Hogg JC, van Eeden SF. The effect of repeated exposure to particulate air pollution (PM10) on the bone marrow. Am J Respir Crit Care Med 2001;163:201-209.
26. Ruckerl R, Ibald-Mulli A, Koenig W, Schneider A, Woelke G, Cyrys J, Heinrich J, Marder V, Frampton M, Wichmann HE, et al. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Am J Respir Crit Care Med 2006;173:432-441.
27. van Eeden SF, Tan WC, Suwa T, Mukae H, Terashima T, Fujii T, Qui D, Vincent R, Hogg JC. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med 2001;164:826-830.
28. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-876.
29. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GD, World MJ, Humphries SE, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:2063-2069.
30. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-1011.
31. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
32. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-679.
33. Aronson D, Sheikh-Ahmad M, Avizohar O, Kerner A, Sella R, Bartha P, Markiewicz W, Levy Y, Brook GJ. C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 2004;176:173-179.
34. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
35. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148-1150.
36. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
37. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-4200.
38. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ, Aronson D. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193-197.